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Introduction
Cytokine gene transfer to tumor cells has been recently developed as an attractive mechanism of drug delivery in situ without the toxic effects associated with systemic administration. Murine tumor cells engineered ex vivo to secrete different cytokines such as IL-2, TNF␣, GM-CSF and others, have shown a decreased growth in syngeneic mice. Tumor cell expression of IL-2, IL-4, IL-6, IL-7, TNF-␣, IFN␥ and IL-12 induced, in certain murine models, a concomitant development of a T cell-dependent immunity to the parental tumor cells. 1 IL-10, originally named cytokine synthesis inhibitory factor is a product of Th2 cells and an inhibitor of cytokine production by Th1 cells.
2 IL-10 was subsequently found to be produced by B cells, macrophages, thymocytes and keratinocytes. 3 IL-10 can also inhibit concanavalin A-induced T cell activation and IL-2 production by Th1 cells, by suppressing the effector functions of antigen-presenting macrophages mediated by B7/CD80 4 but had no effect on dendritic cell-induced Th1 clones and CD4
+ cell proliferation. 3 In addition to having these effects on cytokine production, IL-10 is effective as a costimulator for the growth of B cells, mast cells and thymocytes. [5] [6] [7] In addition, IL10 may render tumor cells completely resistant to CTL lysis through a mechanism involving HLA I down-regulation. 8 In spite of the evidence that IL-10 has Th1-immunosuppressive and antiinflammatory effects, it has been demonstrated that the ectopic expression of IL-10 in murine B16 melanoma, 9 and in two murine models of mammary tumors 10, 11 may induce the loss of tumorigenicity mainly through an NK cell-dependent mechanism. The involvement of NK was suggested to be the result of MHC class I down-regulation. 12 In view of the conflicting findings regarding IL-10 effects on immune responses, we decided to study the mechanisms associated with tumor cell growth following expression of IL-10 in CT26 colon carcinoma cells. The present data show that ectopic expression of IL-10 induced the inhibition of tumor cell growth through nonimmune and immune-based mechanisms. IL-10 expression inhibits the metastatic potential of CT26 cells as assessed by different in vitro parameters. In addition, the antitumor immune response which involves both CD4 + and CD8 + T cells, occurs in the context of a shift toward a Th2 response.
Results
Tumor cell isolation, IL-10 production and in vitro growth characteristics Parental CT26 cells, which showed no IL-10 expression, were transduced with the retroviral vector pBabe Puro mIL-10 (CT26-IL10) and with the non-modified pBabe retroviral vector (CT26-B). CT26-IL10 cells showed no difference in their in vitro growth kinetics on plastic surface compared with parental or CT26-B cells (not shown). But, at a density of 300 seeded cells per 24-well plate, an inhibition of 36% in the clonogenic capacity of CT26-IL10 cells was observed compared with CT26-B cells (70 ± 12.8 versus 46 ± 3.3 colonies, respectively, P Ͻ 0.05) while 50% inhibition was observed at a density of 3000 seeded cells per 24-well plate (219 ± 74.8 versus 442 ± 36 colonies of CT26-IL10 and CT26-B cells, respectively, P Ͻ 0.05), demonstrating that IL-10 may directly affect the clonogenic growth ability of CT26 cells in semi-solid media.
In vitro migration and invasive capacity of engineered cells The ectopic expression of IL-10 was able to affect other features of CT26 cells. By using reconstituted basement membranes, we observed almost 50% inhibition in the in vitro invasive capacity of CT26-IL10 cells compared with CT26-B cells (Figure 1a) . Two isolated clones, CT26-2F and CT26-3E, also showed 50-65% inhibition in their capacity to penetrate Matrigel (Figure 1a ). IL-10 effect was even stronger when B16 cells were used, since inhi- bitions of 40-80% were observed when the bulk of IL-10-transfected cells or isolated cell clones were used ( Figure  1a ). Gelatin and casein zymograms showed no difference between conditioned media obtained from both cell types producing IL-10 compared with vector-transduced cells (not shown). In addition, IL-10 expression did not affect the adhesive capacity of CT26-B and B16-B cells to Matrigel. However, IL10 expression by CT26 and B16 cells induced 50-75% inhibition in the in vitro migration in transwell chambers in response to chemotactic stimulus, compared with control cells (Figure 1b) .
In vivo growth in immunocompetent host of IL-10-producing CT26 cells We studied the growth competence in syngeneic mice of IL-10-producing CT26 cells. In the range of 1 × Number of mice which rejected cell challenge per total challenged mice.
In general, the experiments were terminated after 10 weeks, although in some cases, mice were followed for 16-18 weeks.
Parallel experiments performed with B16 cells demonstrated that 50-83% of mice remained free of tumors when injected with 5 × 10 5 B16-IL10 cells. As expected, all the mice injected with B16-B cells developed tumors.
The involvement of host immune cells in tumor rejection
Histological analysis of the site of injection of CT26-IL10 cells revealed the presence of microscopic tumors during the first 3-5 days which then ceased growing. Twentyfour hours after injection, neutrophils and less lymphocytes and macrophages massively infiltrated the site of injection of CT26-IL10 cells. After 5 days, we observed a strong decrease in neutrophil infiltrate, with an increase in infiltrating lymphocytes and macrophages.
This evidence led us to determine the contribution of the host immune system to the diminished tumorigenicity. CT26-IL10 cell growth was first investigated in nude athymic mice. The antitumor effect of CT26-IL10 cells observed in immunocompetent mice was completely abolished in nude athymic mice, suggesting that T cells were responsible for the antitumor response ( Figure 2a ). Parallel studies performed with B16 melanoma cells provided evidence that the inhibition of tumor growth observed in immunocompetent C57Bl mice following injection of B16-IL10 cells, was still observed in nude mice, suggesting that non-T cells were involved in tumor rejection ( Figure 2b ). Following these experiments, a ser- 15 in rodent malaria infection. In order to characterize further the immune response elicited by IL-10 expression in tumor cells, we assessed total circulating levels and CT26-specific levels of IgG1 and IgG2a subclasses as markers of Th2 and Th1 responses, respectively. A statistically significant increase in total IgG1 circulating levels was observed in mice injected with CT26-IL10 cells compared with control CT26-B cells (Table 2 , P Ͻ 0.01-0.001). In addition, a slight decrease in total IgG2a circulating levels was observed in mice injected with CT26-IL10 cells compared with those injected with CT26-B cells (Table 2 , P Ͻ 0.05-0.01). Thus, an overall tendency towards a systemic Th2 response was observed ( Table 2 , see IgG2a/IgG1 ratio).
When the CT26-specific Ig levels were assessed, we observed a 2.5 to five-fold increase in CT26-specific IgG1 levels compared with control CT26-B cells (Table 3 , P Ͻ 0.01). A decrease in IgG2a levels was also observed. The IgG2a/IgG1 ratio showed a clear balance towards a Th2 response. 
IL-4 and IFN␥ production by spleen cells
It is widely accepted that IFN␥ may induce Th1 cell differentiation and inhibit Th2 cells; while IL-4 opposes the effect of IFN␥ inducing Th2 differentiation and inhibiting Th1. 14, 16 To evaluate further the immune response following IL-10 expression by tumor cells, spleen cells obtained from mice injected with 1 × 10 6 CT26-IL10 cells were studied for their production of IFN␥ and IL-4 at the time of challenge with parental cells. We observed no changes in the amount of IFN␥ produced compared with control cells (1.6 ± 0.2 and 1.3 ± 0.04 ng/ml of IFN␥ for CT26-B and CT26-IL10 injected cells, respectively, using normal serum as a base line, P Ͼ 0.05, six mice per group). However, spleen cells obtained from mice injected with CT26-IL10 cells produced more IL-4 than those injected with CT26-B cells (12.0 ± 0.5 and 7.8 ± 0.3 U/ml, respectively, P Ͻ 0.01). In addition, spleen cells obtained from five mice which remained alive for 4 months following an initial injection of 1 × 10 6 CT26-IL10 cells and challenged with parental cells, were also tested for cytokine production. We found no changes in the amount of IFN␥ produced by spleen cells obtained from these mice com-pared with non-injected age-matched mice (2.7 ± 0.1 and 2.6 ± 0.3 ng/ml of IFN␥, respectively, P Ͼ 0.05). However, these spleen cells produced more IL-4 than those cells obtained from the non-injected age-matched mice (20.2 ± 1.1 and 15.9 ± 0.5, respectively, P Ͻ 0.001).
Discussion
Several studies have demonstrated that different tumor cells lost their tumorigenic capacity when engineered to express IL-10.
9,10,17, 18 The antitumor response associated with IL-10 expression contradicted the current view, which considered IL-10 as an immunosuppressor, antiinflammatory and anti-cytotoxic agent in vivo. [19] [20] [21] Indeed, IL-10 is produced by Th2 cells, inhibits cytokine production by Th1 cells, macrophages, neutrophils and NK cells, and induces differentiation of B cells. 2, 3 No previous study has aimed at dissecting the effect of IL-10 on the different components of an immune response trying to reconcile this contradictory evidence.
As shown previously in other experimental models, the ectopic expression of IL-10 by CT26 colon carcinoma cells inhibited tumor cell growth in most of the mice. A restoration of tumor cell growth was observed when tumor cells were injected in nude mice. Both CD4 + and CD8 + T cells were required for effective CT26 cell rejection, since depletion of either subset before injection of tumor cells expressing IL-10 abrogated the antitumor response. On the other hand, depletion of NK cells had a minor effect on tumor cell rejection induced by IL-10 expression in CT26 cells. Since lymphoid dendritic cells express CD8 markers, we cannot rule out that immature precursors of this cell type might also have been depleted, although this immune cell type has been mainly involved in the induction of self tolerance. 22 Parallel depletion studies performed with B16 cells showed no involvement of T cells confirming previous evidence indicating that NK cells were mainly responsible for tumor rejection in the B16 melanoma model. 13 The involvement of either NK or T cell subset in an antitumor response was suggested to be related to MHC class I expression by the tumor cells. Down-regulation of MHC class I levels was associated with increased NK activity. 12 Interestingly, MHC class I down-regulation by IL-10 was suggested as a tumor cell mechanism to evade the immune response. 8 More recently, it has been shown that IL-10 expression by murine RMA lymphoma cells, J588L plasmocytoma cells and 410.4 mammary tumor cells, down-regulated MHC class I expression with a simultaneous increase in NK antitumor cell activity. 12, 23 The present data clearly indicate that IL-10 expression by tumor cells may affect MHC class I expression differently in different tumor cell lines. A clear down-regulation of MHC class I expression was observed in B16 cells which correlated with the reported NK involvement in tumor rejection. However, no effect and even increased levels of MHC class I were observed in CT26 cells, which correlated with T cell involvement. Thus, it can be concluded that T cell involvement in CT26 rejection might be related to the lack of capacity of IL-10 to down-regulate MHC class I levels in these cells. CD4 + and CD8 + T cell involvement in tumor cell rejection following IL-10 expression occurred simultaneously with a shift towards a systemic and CT26-specific Th2 response. The shift towards a systemic and tumor-specific Th2 response was mainly the result of increased IgG1 levels while a slight decrease in IgG2a levels was also observed. This systemic and CT26-specific Th2 response was consistent with the immunosuppressive effect observed following administration of IL-10 to human volunteers 21 and the current view regarding IL-10 as an immunosuppressive cytokine. The induction of IL-4 production and the lack of changes in IFN␥ production by spleen cells following injection of CT26-IL10 cells were also consistent with a shift towards a Th2 phenotype. Thus, it appears evident that recruitment and activation of a T cell-mediated antitumor response and a systemic and specific Th2 phenotype may occur simultaneously following IL-10 expression by tumor cells.
Recently, Sarvetnick 24 raised the concept of cytokinemediated localized immunoprotection to explain the immunosuppressor effect of TNF␣ in the non-obese diabetic model. Although TNF␣ is currently viewed as a proinflammatory agent, it was demonstrated that TNF␣ expression in the pancreas as a result of gene transfer, protected mice from diabetogenic citotoxic T cells. 25 Recently, we have also shown that the locally produced TNF receptor was of benefit for treating collagen-induced arthritis in animal models, and found no correlation between circulating levels of p75 TNFR and clinical benefits. 26 Thus, many immune responses appear to remain localized, in agreement with the present data suggesting that IL-10 might inhibit tumor cell growth by the recruitment and activation of T cells at the site of tumor cell injection, with the simultaneous induction of a Th2 response. The sequence of events, and the mechanisms involved in the recruitment and activation of T cells in vivo remain to be elucidated. In particular, the identity of the cells which may prime CD4 + T cells given the fact that CT26 do not express MHC class II and IL-10 was shown to prevent macrophage and dendritic cell accumulation in the vicinity of certain tumor models.
17, 27 The present data and previous evidence showing that IL-10 may act as a potent leukocyte chemoattractant in vivo 28 and in vitro 29 suggest that IL-10 may inhibit tumor cell growth by accelerating leukocyte recruitment to the site of injection. It can be hypothesized that once T cells reach the tumor target, they can be activated in situ to eliminate the tumor cells. 30 As a result of tumor lysis, cell debris may become available to antigen-presenting cells, both at the site of tumor rejection and in draining lymph nodes, allowing for CD4 + T cell activation. The presence of macrophages at the site of CT26-IL10 cell injection may contribute to CD4 + T cell priming. The present data demonstrated that a non-immune pathway might contribute to the abrogation of the malignant phenotype of tumor cells following IL-10 gene transfer. In agreement with previous evidence observed with other tumorigenic cell lines, IL-10 expression had no effect on CT26 cell growth on plastic surface. However, the in vitro growth of CT26 cells was impaired when the anchorage-independent growth capacity was assessed. Moreover, the migration and invasion capacity was also inhibited following IL-10 expression by CT26 and B16 cells. In contrast, we found no changes in the capacity of IL-10-transduced cells to attach to a reconstituted matrix. Since CT26-IL10 growth was not impaired in nude mice, it can be suggested that the rejection of primary tumors is mainly an immune-mediated event. In contrast, we can hypothesize that the dissemination of tumor cells to form secondary tumors will be affected by IL-10 expression, since metastatic dissemination is based on the capacity of the malignant cell to detach from the neighbor cells, and migrate and invade the surrounding matrix. No previous evidence was provided on a direct inhibitory effect of IL-10 on the malignant phenotype of tumor cells, but the lack of tumorigenicity of Lewis lung carcinoma cells following IL-6 gene transfer was attributed both to an immune-mediated response and to a direct inhibition of the clonogenic capacity of tumor cells. 31 The decrease in the migration and invasive capacity, and the up-regulation of CD44 following IL-10 expression by CT26 cells, might impair tumor cell-host stroma interaction in vivo and induce the release of cytokines from the extracellular matrix. 32 Cytokine release from the extracellular matrix might affect the outcome of the immune response and the profile of immune cells involved in tumor rejection. This effect of IL-10 on tumor cell growth might be responsible in part for the antitumorigenic effect observed in previous studies following systemic administration of IL-10. 33 Elucidating the exact mechanism by which IL-10 exerts its antitumor effect may provide an advantage in combination therapy, allowing lowering the dose of the drug (or gene) to reduce its side-effects while still preserving its therapeutic activity.
Materials and methods

Cell lines and mice
The CT26 mouse colon carcinoma cell line 34 obtained from the MD Anderson Cancer Research Center (Houston, TX, USA) and the B16 (F1) mouse melanoma cell line purchased from the American Type Culture Collection (ATCC, CRL 6323; Rockville, MD, USA) were routinely maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal calf serum, 2 mm glutamine, 2.5 units/ml penicillin and 2.5 g/ml streptomycin. The amphotropic GP+envAm12 packaging cell line was maintained in DMEM + 10% newborn calf serum. 32 Male Balb/c and Balb/c nu/nu mice (8-12 weeks old) and C57Bl mice were used for in vivo experiments. The immunocompetent mice were obtained from the animal facility of the Angel H Roffo Institute (Buenos Aires, Argentina), while the nude mice were obtained from the animal facility of the Faculty of Veterinary, University of La Plata, Buenos Aires, Argentina.
Recombinant retroviral construction, transfection of packaging cells and transduction of target cells
The full-length cDNA corresponding to murine IL-10 (DNAX, Palo Alto, CA, USA), 35 was isolated as a 1.2 kb XhoI fragment and cloned into the SalI site of the vector pBABE Puro (kindly provided by Drs Morgenstern and Land, ICRF, London, UK). 36 Twenty micrograms of retroviral vector without insert, or recombinant retroviral vector, were used for transfection of GP+envAm12 cells, 37 by coprecipitation with calcium phosphate. Puromycin (1.5 g/ml) resistant cells were selected and pooled. Several clones were isolated by ring cloning and evaluated for their production of IL-10. Retroviral transduction of target cells was performed as described. 26, 38 IL-10 levels were measured using a biotinylated rat anti-mouse IL-10 (Pharmingen, Cambridge, UK) according to Mossman et al. 39 The bulk culture of CT26-IL10 cells and the isolated cell clones CT26-2F and CT26-3E produced 5.8, 1.9 and 3.8 ng/ml per 10 5 cells/24 h, respectively. The bulk culture of B16-IL10 cells and the isolated cell clones B16-1A and B16-1B produced 3.6, 6.6 and 0.6 ng/ml pro 10 5 cells/24 h, respectively.
Assessment of total levels of circulating IgGs
A capture ELISA using sheep anti-mouse IgG1 and IgG2a (at 2 g/ml in PBS; Binding Site Ltd, Birmingham, UK) sensitized plates were used for quantification of total serum levels of IgG1 and IgG2a. Following blocking with 2% bovine serum albumin and three washes with 0.05% Tween in PBS (Tween-PBS), serial dilutions of serum samples were added to each well and incubated overnight at 4°C. After washing with Tween-PBS, plates were incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG1 or IgG2a (Binding Site Ltd). Levels of bound IgGs were obtained by extrapolation using standard curves obtained from optical density of known inputs of affinity purified IgG1 and IgG2a (Binding Site Ltd). Color was developed using orthophenylenediamine + H 2 O 2 . Each determination was performed in triplicate.
Assessment of anti-CT26-specific IgGs 1 × 10 5 exponentially growing CT26 cells were plated in each well of a 96-well plate. Following overnight incubation at 37°C and 5% CO 2 , cells were washed with PBS, fixed with 3.7% paraformaldehyde in PBS, and washed with PBS. Non-occupied sites in the wells were blocked with 20% fetal bovine serum for 1 h at room temperature and washed with Tween-PBS. Serial dilutions of the different sera diluted in PBS were incubated overnight at 4°C. Bound IgG subclasses 1 and 2a were detected by incubation with horseradish peroxidase-conjugated sheep anti-mouse IgG1 and IgG2a, respectively (Binding Site Ltd). Quantification was performed as described above from a standard curve. Each determination was performed in triplicate.
Isolation of spleen cells and assessment of IL4 and IFN␥ levels Splenic cells were isolated following mechanical disaggregation. Supernatants corresponding to 3 × 10 6 spleen cells per well of a 24-well plate, incubated for 24 h with 5 g/ml concanavalin A at 37°C, were tested for IL-4 and IFN␥ levels. An immunoassay was performed using capture and biotinylated detection antibodies (Pharmingen, San Diego, CA, USA). The reaction was developed using peroxidase-conjugated avidine and orthophenylenediamine + H 2 O 2 .
In vitro growth and clonogenic assays IL-10-producing CT26 cells and vector-transduced cells were trypsinized, washed and plated in triplicate in 24-well plates at 10-40 thousand cells per well in medium without puromycin. Cell growth was evaluated using the MTT assay. 40 The clonogenic capacity was assayed as described. 41 Cells were seeded at low density (300 cells per 24-well plate) or at high density (3000 cells per 24-well plate).
Cell invasion and chemotactic migration assays
The in vitro invasion capacity of tumor cells was performed essentially as described. 42 Briefly, polycarbonate filters, 8 m pore size, were coated with 5 g of Matrigel (Collaborative Research, Bedford, MA, USA) and dried under a hood. Cells were collected, washed with PBS, resuspended at 1 × 10 6 cells/ml in DMEM:0.1% BSA buffer, and allowed to recover for 1 h at room temperature. After 6-7 h incubation at 37°C in 5% CO 2 , the cells on the upper face of the filter were removed, filters were fixed in methanol, and stained with hematoxylin. The chemotactic assays were performed in a similar fashion without Matrigel coating. Conditioned medium for in vitro migration and invasion assays was obtained by incubating NIH-3T3 cells at confluence for 24 h in serumfree medium. This medium was placed in the lower compartment of the transwell as a source of chemoattractant. Cells from at least 10 different areas of the lower surface were counted. Zymograms of cell-conditioned media were performed as described. 42 In vivo experiments Mice were given s.c. injections into the right flank of 1 × 10 5 -1 × 10 6 parental, vector-transduced or IL-10 genetransduced tumor cells, in a total volume of 0.1 ml. Tumor growth was evaluated by measuring the two perpendicular diameters with calipers. Depending on the experiment, mice were killed for humane reasons. For evaluating the establishment of an immune memory, mice were challenged with the same number of parental cells injected s.c. in the opposite flank, 15-18 days after the first injection, without removing the primary tumor. Tumor growth was followed as previously described.
Cell depletion
Mice were depleted of T lymphocyte subsets using monoclonal antibody (mAb) YTS 191.1 for CD4 + cells and mAb YTS 169.4 for CD8 + cells, 43 and from NK cells and NK cell subsets, using PK136 and 4D11 hybridoma clones purchased from ATCC (HB-191 and HB240, respectively). Cell depletion was started 1 day before tumor cell injection for 3 consecutive days by injecting 0.5 mg of antibodies into 0.3 ml of PBS. Thereafter, mice were injected with the different antibodies once a week until the end of the experiment. Examination of splenocytes by FACS demonstrated the specific elimination of 92-95% of the specific cell subset. Rat hybridomas were grown in athymic mice. Ascitic fluid was collected, spun down to eliminate cells and debris, precipitated with 50% saturated ammonium sulfate and purified using Protein G Sepharose (Pharmacia, Uppsala, Sweden). Isotypematched mAbs were used as controls.
Flow cytometric analysis
Isolated tumor cells detached from plastic with citrate buffer, were incubated at 4°C for 1 h with 10-fold concentrated hybridoma supernatant recognizing MHC class I (ATCC; TIB 126), MHC class II (ATCC; HB 225) and CD44 antigen (ATCC; TIB 240) in the presence of 10% goat serum (for MHC class I and II) and rabbit serum (for CD44). Following washing with PBS, cells were incubated at 4°C for 1 h with 1:100 dilution of FITC-conjugated AffiniPure goat anti-rat IgG (for MHC class I and II, RDI, Flanders, NJ, USA) or FITC-conjugated AffiniPure rabbit anti-Armenian hamster IgG (for CD44; RDI). After washing with PBS, 1 × 10 4 cells were analyzed per sample in a FACStar flow cytometer (Becton Dickinson, San Jose, CA, USA).
Statistical analysis
The significance of differences was determined by using one way analysis of variance (ANOVA) and TukeyKramer multiple comparison tests.
